~33 spots leftby Apr 2026

TMS for Suicide

Recruiting in Palo Alto (17 mi)
JC
Overseen byJoan Camprodon, MD/PhD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: Massachusetts General Hospital
No Placebo Group
Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).

Do I have to stop taking my current medications for this trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, it does exclude participants with certain conditions and devices, so it's best to discuss your specific medications with the trial coordinators.

What data supports the idea that TMS for Suicide is an effective treatment?

The available research shows that TMS for Suicide, specifically using intermittent theta burst stimulation (iTBS), can effectively reduce suicidal thoughts in people with depression. One study found a significant decrease in suicide risk that lasted up to a month, even in those who did not respond to depression treatment. Another study confirmed that iTBS is a safe and effective way to reduce suicidal thoughts in both adults and adolescents with major depressive disorder. These findings suggest that iTBS can be a promising treatment for reducing suicide risk in people with depression.12345

What safety data exists for TMS in treating suicide risk?

The safety of intermittent theta burst stimulation (iTBS) for treating suicide risk has been evaluated in several studies. An accelerated iTBS protocol was found to be safe and well-tolerated in therapy-resistant depressed patients, with no worsening of suicidal ideation observed. Another study confirmed iTBS as a safe treatment for reducing suicidal ideation in adults with major depressive disorder. Additionally, a case series on prolonged iTBS reported some tolerability issues, but overall, iTBS is considered a safe brain stimulation treatment for addressing suicide risk.12356

Is the treatment Intermittent Theta Burst Stimulation (iTBS) a promising treatment for reducing suicide risk?

Yes, Intermittent Theta Burst Stimulation (iTBS) is a promising treatment for reducing suicide risk. Studies show that it can safely and effectively lower suicidal thoughts in people with depression, including those who have not responded to other treatments.12345

Research Team

JC

Joan Camprodon, MD/PhD

Principal Investigator

6177265348

Eligibility Criteria

This trial is for adults aged 18-60 with major depressive disorder (MDD) or borderline personality disorder (BPD), who are experiencing suicidal thoughts and behaviors. Participants must own a smartphone and be able to use it during their inpatient stay. Those with metal implants, history of seizures, recent substance abuse, or certain psychopathologies like psychosis are not eligible.

Inclusion Criteria

My doctor has just given me permission to use my smart phone during my inpatient stay
You own a smartphone, such as an Android or an Apple device.
You have expressed thoughts of hurting or killing yourself.
See 2 more

Exclusion Criteria

Prior neurosurgical procedure.
You have metal in your body that can be affected by magnets or have had an injury to your eyes from metal.
Inability to meet the safety criteria for MRI scanning according to the protocols of the Department of Radiology.
See 5 more

Treatment Details

Interventions

  • Intermittent Theta Burst Transcranial Magnetic Stimulation (Active) (Non-invasive Brain Stimulation)
  • Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham) (Non-invasive Brain Stimulation)
Trial OverviewThe study tests intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) on the inferior parietal lobule to see if it lowers suicide risk in patients with MDD or BPD. It compares active iTBS-TMS treatment against a sham (placebo-like) procedure.
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: MDE and Active iTBS-TMSExperimental Treatment1 Intervention
This group will consist of patients diagnosed with MDE that are receiving active iTBS-TMS.
Group II: BPD and Active iTBS-TMSExperimental Treatment1 Intervention
This group will consist of patients diagnosed with BPD that are receiving active iTBS-TMS.
Group III: MDE and Sham iTBS-TMSPlacebo Group1 Intervention
This group will consist of patients diagnosed with MDE that are receiving sham iTBS-TMS.
Group IV: BPD and Sham iTBS-TMSPlacebo Group1 Intervention
This group will consist of patients diagnosed with BPD that are receiving sham iTBS-TMS.

Intermittent Theta Burst Transcranial Magnetic Stimulation (Active) is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as iTBS for:
  • Major Depressive Disorder (MDD)
  • Treatment-resistant depression
🇪🇺 Approved in European Union as iTBS for:
  • Major Depressive Disorder (MDD)
  • Treatment-resistant depression

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
Massachusetts General HospitalBoston, MA
Loading ...

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3066
Patients Recruited
13,430,000+

Findings from Research

Accelerated Intermittent Theta Burst Stimulation for Suicide Risk in Therapy-Resistant Depressed Patients: A Randomized, Sham-Controlled Trial.Desmyter, S., Duprat, R., Baeken, C., et al.[2020]
Effect of intermittent theta burst stimulation on suicidal ideation and depressive symptoms in adolescent depression with suicide attempt: A randomized sham-controlled study.Zhao, Y., He, Z., Luo, W., et al.[2023]
The acute effects of accelerated repetitive Transcranial Magnetic Stimulation on suicide risk in unipolar depression: preliminary results.Desmyter, S., Duprat, R., Baeken, C., et al.[2022]
Effect of high frequency versus theta-burst repetitive transcranial magnetic stimulation on suicidality in patients with treatment-resistant depression.Mehta, S., Downar, J., Mulsant, BH., et al.[2023]
In a study involving 81 participants with major depressive disorder, accelerated intermittent theta burst stimulation (iTBS) significantly reduced suicidality and depressive symptoms over a 6-week period, indicating its potential as an effective treatment.
The intervention was found to be safe, with no serious adverse events reported, and showed particularly pronounced anti-suicidal effects in individuals with higher risk profiles.
Suicidality and relief of depressive symptoms with intermittent theta burst stimulation in a sham-controlled randomized clinical trial.Wilkening, J., Witteler, F., Goya-Maldonado, R.[2023]
Prolonged intermittent theta burst stimulation in the treatment of major depressive disorder: a case series.Richard, M., Noiseux, C., Desbeaumes Jodoin, V., et al.[2022]

References

Accelerated Intermittent Theta Burst Stimulation for Suicide Risk in Therapy-Resistant Depressed Patients: A Randomized, Sham-Controlled Trial. [2020]
Effect of intermittent theta burst stimulation on suicidal ideation and depressive symptoms in adolescent depression with suicide attempt: A randomized sham-controlled study. [2023]
The acute effects of accelerated repetitive Transcranial Magnetic Stimulation on suicide risk in unipolar depression: preliminary results. [2022]
Effect of high frequency versus theta-burst repetitive transcranial magnetic stimulation on suicidality in patients with treatment-resistant depression. [2023]
Suicidality and relief of depressive symptoms with intermittent theta burst stimulation in a sham-controlled randomized clinical trial. [2023]
Prolonged intermittent theta burst stimulation in the treatment of major depressive disorder: a case series. [2022]